AI Terminal
Theranexus
Report Publication Announcement • Dec 20, 2022
1703_iss_2022-12-20_8c711376-f2ae-41fc-93ec-3b85dd851c66.pdf
Report Publication Announcement
Open in ViewerOpens in native device viewer
THERANEXUS ANNOUNCES PARTICIPATION IN THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE JANUARY 9-12, 2023 IN SAN FRANCISCO
Lyon, France – 20 December 2022 – 6:00pm CET - Theranexus, an innovative biopharmaceutical company innovating in the treatment of rare neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, announced today that it will participate in the 41st Annual J.P. Morgan Healthcare Conference, bringing together all the key players in the healthcare industry, from January 9 to 12, 2023 in San Francisco, USA.
The conference will offer an opportunity to present the Company's new positioning in rare neurological diseases and the latest advances in its Batten disease program to major industry players. In parallel, Theranexus will participate in investor meetings at the Biotech Showcase 2023 to be held from January 9 to 11, 2023 in San Francisco.
The day before this event, Theranexus will also speak at the Sachs Associates' 6 th Annual Neuroscience Innovation Forum on January 8, 2023 (https://www.sachsforum.com/6nif-about.html) with a presentation of the company and its programs. Theranexus management will also participate in a roundtable discussion on the theme "Rare and orphan diseases new modalities panel".
About Theranexus
Theranexus is an innovative biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). It specializes in the treatment of central nervous system disorders and is a pioneer in the development of drug candidates targeting both neurons and glial cells.
The company has a unique platform for the identification and characterization of advanced therapy drug candidates targeting rare neurological disorders and an initial drug candidate in clinical development for Batten disease. Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).
Next financial publication:
18 January 2023 (before stock exchange) : Cash position as at December 31th 2022
More information at http://www.theranexus.com Click and follow us on Twitter and Linkedln
Contacts
THERANEXUS Thierry Lambert Chief Financial Officer [email protected]
NEWCAP Théo Martin/Pierre Laurent Investor Relations +33 (0)1 44 71 94 97 [email protected]
FP2COM Florence Portejoie Media Relations + 33 (0)6 07 76 82 83 [email protected]